<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850265</url>
  </required_header>
  <id_info>
    <org_study_id>FORM-DPB-extrafine</org_study_id>
    <nct_id>NCT00850265</nct_id>
  </id_info>
  <brief_title>Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma</brief_title>
  <official_title>Rol of Spacer in the Combined Treatment With Extrafine Beclomethasone-Formoterol in Stable Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Requena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Requena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined inhaled treatment with long acting adrenergics and steroids in an unique inhaler
      plays an important role in the management of non-mild asthma. Some studies have demonstrated
      that the use of spacers achieve better lung deposition and decrease the number of side
      effects. Recently a new combined treatment for asthma has been developed (extrafine
      formoterol plus beclomethasone dipropionate). The small size of the extrafine particles of
      this new combination get the small airway and theorically improve their positive effect. Some
      authors have stated that the use of a spacer with extrafine particle could decrease the
      effectiveness of this treatment due to the adhesion of particles on the walls of the spacer
      because of the electrostatic characteristics of plastic spacers. However, there are no
      clinical or functional studies demonstrating the role of this phenomena in the control of
      asthmatic patients. The investigators' hypothesis is that the benefit of using spacers with
      this new treatment is at least equal in magnitude than the loss of efficacy because of the
      adhesion of particles on the wall of the spacer and then the investigators hypothesized that
      the use of spacer with extrafine formoterol-beclomethasone do not suppose a decrease in
      clinical or functional control in stable moderate-severe asthma patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Questionnaire</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Flow</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthmatics Symptoms</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhalation technique</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extrafine formoterol plus beclomethasone with spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Spacer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Extrafine formoterol plus beclomethasone without spacer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Volumatic spacer</intervention_name>
    <description>A spacer is a plastic device to inhaler medication</description>
    <arm_group_label>Spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate-severe asthma

          -  Stable asthma

          -  18-75 years old

        Exclusion Criteria:

          -  Exacerbation of asthma

          -  Instability with the study treatment

          -  Other cardiopulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Requena</name>
      <address>
        <city>Requena-Valencia</city>
        <state>Valencia</state>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>March 26, 2009</last_update_submitted>
  <last_update_submitted_qc>March 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Miguel Angel Martínez García</name_title>
    <organization>Hospital General de Requena</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Formoterol</keyword>
  <keyword>Beclomethasone</keyword>
  <keyword>Extrafine formulation</keyword>
  <keyword>Spacer</keyword>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

